Edgewise Therapeutics, Inc. (EWTX) closed the last trading session at $13.89, gaining 0.4% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of $39.17 indicates an 182% upside potential.The mean estimate comprises 12 short-term price targets with a standard deviation of $12.96. While the lowest estimate of $14.00 indicates a 0.8% increase from the current price level, the most optimisti ...

Company Overview - EVI Industries, Inc. specializes in the distribution and service of commercial laundry and dry cleaning equipment, operating in a niche market that serves industries such as hospitality, healthcare, and education [1] Financial Performance - On September 10, 2025, EVI's Q4 2025 earnings call provided insights into the company's financial results and future plans, with CEO Henry Nahmad discussing strategic growth initiatives [2][5] - The current stock price of EVI is $27.99, reflecting a slight increase of 0.74% or $0.205, with a trading range today between $27.96 and $28.39 [3] - Over the past year, EVI's stock has fluctuated between a high of $29.29 and a low of $14.99, indicating volatility in market performance [3] Market Position and Outlook - Michael Shlisky from D.A. Davidson has set a price target of $33 for EVI, suggesting a potential increase of approximately 17.65% from its current price [2][5] - The market capitalization of EVI is approximately $357.18 million, highlighting its significant presence in the commercial laundry equipment sector [3] - The current trading volume for EVI is 1,409 shares, indicating relatively low trading activity, which may be attributed to the niche nature of the industry or investor caution following the recent earnings call [4]

Mission Produce, Inc. (AVO) closed the last trading session at $12.85, gaining 3.7% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of $17.33 indicates a 34.9% upside potential.The mean estimate comprises three short-term price targets with a standard deviation of $0.58. While the lowest estimate of $17.00 indicates a 32.3% increase from the current price level, the most optimistic an ...

Electromed, Inc. (ELMD) closed the last trading session at $23.88, gaining 26.2% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of $36.33 indicates a 52.1% upside potential.The mean estimate comprises three short-term price targets with a standard deviation of $1.53. While the lowest estimate of $35.00 indicates a 46.6% increase from the current price level, the most optimistic analy ...

Group 1 - Knightscope, Inc. (KSCP) shares have increased by 4.7% over the past four weeks, closing at $5.82, with a mean price target of $15.33 indicating a potential upside of 163.4% [1] - The mean estimate includes three short-term price targets with a standard deviation of $9.45, where the lowest estimate of $8.00 suggests a 37.5% increase, and the highest estimate of $26.00 indicates a potential surge of 346.7% [2] - Analysts show a strong agreement in revising earnings estimates higher, with the Zacks Consensus Estimate for the current year increasing by 18.2% over the past month, indicating positive earnings prospects for KSCP [11][12] Group 2 - KSCP holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates, suggesting a strong potential upside in the near term [13] - While price targets can be misleading, the direction indicated by the consensus price target may serve as a useful guide for potential price movement [10][14]

Core Viewpoint - A-Mark Precious Metals (AMRK) has seen a 7.6% increase in share price over the past four weeks, closing at $25.01, with analysts suggesting a potential upside of 61.9% based on a mean price target of $40.5 [1][11]. Price Targets - The average price target for AMRK ranges from a low of $29.00 to a high of $63.00, with a standard deviation of $15.8, indicating variability among analysts [2][9]. - The lowest estimate suggests a 16% increase from the current price, while the highest estimate indicates a potential upside of 151.9% [2]. Analyst Sentiment - Analysts have shown increasing optimism regarding AMRK's earnings prospects, with a strong consensus in revising EPS estimates higher, which correlates with potential stock price movements [4][11]. - Over the past 30 days, one estimate has increased, leading to a 26.1% rise in the Zacks Consensus Estimate for the current year [12]. Zacks Rank - AMRK holds a Zacks Rank 1 (Strong Buy), placing it in the top 5% of over 4,000 ranked stocks based on earnings estimate factors, indicating strong potential for upside [13]. Conclusion on Price Targets - While the consensus price target may not be a reliable indicator of the extent of AMRK's potential gains, it does provide a directional guide for price movement [14].

Group 1 - Enliven Therapeutics, Inc. (ELVN) shares have increased by 0.8% over the past four weeks, closing at $19.92, with a mean price target of $41.13 indicating a potential upside of 106.5% [1] - The average of eight short-term price targets ranges from a low of $33.00 to a high of $52.00, with a standard deviation of $6.66, suggesting a potential increase of 65.7% to 161% from the current price [2] - Analysts show strong agreement in revising earnings estimates higher, with two estimates moving up in the last 30 days and the Zacks Consensus Estimate increasing by 8.8% [11][12] Group 2 - ELVN holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates, indicating a strong potential upside [13] - The consensus price target, while not entirely reliable, suggests a positive direction for price movement, which could guide further research into the stock's fundamentals [14]

Group 1: Stock Performance and Price Targets - Exodus Movement, Inc. (EXOD) closed at $27.49, with a 0.6% gain over the past four weeks, and a mean price target of $56.86 indicating a 106.8% upside potential [1] - The average price target ranges from a low of $45.00 to a high of $70.00, with a standard deviation of $8.99, suggesting a potential increase of 63.7% to 154.6% from the current price [2] - Analysts show strong agreement on the company's ability to report better earnings, which supports the view of potential upside [4] Group 2: Analyst Insights and Earnings Estimates - Analysts' growing optimism regarding EXOD's earnings prospects is reflected in the upward revisions of EPS estimates, which correlate with near-term stock price movements [9] - Over the last 30 days, two estimates have increased, leading to a Zacks Consensus Estimate increase of 158% [10] - EXOD holds a Zacks Rank 1 (Strong Buy), placing it in the top 5% of over 4,000 ranked stocks based on earnings estimates [11] Group 3: Price Target Reliability - While consensus price targets are popular among investors, their reliability as indicators of stock price direction is often questioned [3][5] - Analysts may set overly optimistic price targets due to business incentives, which can lead to inflated estimates [6] - A low standard deviation in price targets indicates a high degree of agreement among analysts, serving as a starting point for further research [7]

Core Viewpoint - Omnicell (OMCL) shows potential for significant upside, with a mean price target of $44.4 indicating a 39.4% increase from the current price of $31.86 [1] Price Targets and Analyst Estimates - The mean estimate consists of five short-term price targets with a standard deviation of $9.13, indicating variability among analysts [2] - The lowest estimate is $34.00, suggesting a 6.7% increase, while the highest estimate is $55.00, indicating a potential surge of 72.6% [2] - A low standard deviation among price targets suggests a high degree of agreement among analysts regarding the stock's price movement [9] Earnings Estimates and Analyst Consensus - Analysts have shown increasing optimism about Omnicell's earnings prospects, with a strong consensus in revising EPS estimates higher [11] - The Zacks Consensus Estimate for the current year has risen by 24.6% over the past month, with no negative revisions [12] - OMCL holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates [13] Caution on Price Targets - While consensus price targets are often sought after, they may not reliably indicate actual stock price movements [3][7] - Analysts may set overly optimistic price targets due to business incentives, which can lead to inflated estimates [8] - Investors should approach price targets with skepticism and not rely solely on them for investment decisions [10]

Core Viewpoint - Elastic (ESTC) shares have increased by 6.2% recently, with a mean price target of $119.83 suggesting a potential upside of 40.8% from the current price of $85.09 [1] Price Targets and Analyst Estimates - The mean estimate consists of 24 short-term price targets with a standard deviation of $13.6, indicating variability among analysts [2] - The lowest estimate is $87.00, suggesting a 2.2% increase, while the highest estimate is $150.00, indicating a potential surge of 76.3% [2] - A low standard deviation signifies strong agreement among analysts regarding the stock's price movement [7] Earnings Estimates and Analyst Agreement - Analysts show strong agreement in revising EPS estimates higher, which correlates with potential stock price increases [9] - The Zacks Consensus Estimate for the current year has risen by 1.6% over the past month, with two estimates increasing and no negative revisions [10] - ESTC holds a Zacks Rank 1 (Strong Buy), placing it in the top 5% of over 4,000 ranked stocks based on earnings estimates [11] Caution on Price Targets - While price targets are often sought after, they can mislead investors and should not be the sole basis for investment decisions [5][8] - Analysts may set overly optimistic price targets due to business incentives, which can inflate expectations [6]